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psychosis symptoms did not predict GRF (R-squared = .31, F[5, 92] = 8.09, 
p < .001). Age significantly correlated with GRF (r  =  -.31, p  =  .002). 
Poverty remained a significant predictor of GRF after including age 
(R-squared = .37, F[6, 89] = 8.84, p < .001). Additional cognitive correlates, 
collateral report of childhood ADHD symptoms, prior diagnoses, date of 
psychosis illness onset, and medication history will also be examined.
Discussion: Social functioning was predicted by childhood self-rated inatten-
tion and current negative and disorganized symptoms; however, the relation 
with childhood inattention did not remain after controlling for race/ethnicity. 
Additional analyses will be conducted to assess if race is presenting as a 
proxy for other social determinants, including insurance designation, in this 
sample. Individuals with ADHD experience more difficulty in social settings 
compared to typically developing peers, possibly due to increased need to 
use environmental cues; for individuals who go on to develop psychosis, 
these childhood events are possibly perceived as more stressful, adding to 
risk for psychosis. However, it is unclear if self-report childhood inattention 
– captured here as a putative symptom of ADHD – may be better accounted 
for by premorbid cognitive impairment associated with risk for psychosis. 
Additional research is required to establish this connection.
T77. ASSOCIATION BETWEEN INTRACELLULAR 
INFECTIOUS AGENTS AND SCHIZOPHRENIA
Young-Joon Kwon*1, Bo-Hyun Yoon2, Kwanghun Lee3,  
Moon-Doo Kim4, Beomwoo Nam5, Se-Hoon Shim1,  
Eunsung Lim6
1Soonchunhyang University Cheonan Hospital; 2Naju National 
Hospital; 3College of Medicine, Dongguk University; 4Jeju National 
University; 5School of Medicine, Konkuk University; 6Shinsegae 
Hospital
Background: A number of studies have reported association between 
Toxoplasma gondii (T.  gondii) and Chlamydia infection and the risk of 
schizophrenia. The aim of the present study was to compare the preva-
lence of T. gondii and Chlamydia infection between the schizophrenia and 
normal control subjects and to compare the clinical features between sero-
positive and seronegative schizophrenia patients.
Methods: The rate of serum reactivity to T. gondii, Chlamydia trachomatis 
(C. trachomatis), Chlamydia pneumonia in 96 schizophrenia and 50 con-
trol subjects was investigated using enzyme-linked immunosorbent assay 
and indirect fluorescent antibody technique. The clinical symptoms of the 
schizophrenia patients were scored with Positive and Negative Syndrome 
Scale and a comparative analysis was carried out.
Results: A significant positive association between immunoglobulin G 
(IgG) antibodies to T.  gondii and C.  trachomatis in schizophrenia was 
found, and the odds ratio of schizophrenia associated with IgG antibody 
was found to be 3.22 and 2.86, respectively. The Toxoplasma-seropositive 
schizophrenia patient had higher score on the negative subscale N1 and 
N7 and general psychopathology subscale G13, while C.  trachomatis-
seropositive schizophrenia patient had higher score on the general psycho-
pathology subscale G10.
Discussion: The results from the present study suggest significant associa-
tion between T. gondii, C. trachomatis infection and schizophrenia. In fu-
ture, further studies are needed to elucidate the correlation between the two 
types of infection and schizophrenia.
T78. MORTALITY IN PATIENTS WITH 
SCHIZOPHRENIA ADMITTED FOR INCIDENT 
ISCHEMIC STROKE: A POPULATION-BASED 
COHORT STUDY
Nicholas Chak Lam Yung*1, Joe Kwun Nam Chan1,  
Corine Sau Man Wong1, Philip Chi Fai Or2, Wing Chung Chang3
1The University of Hong Kong; 2Queen Mary Hospital; 3The 
University of Hong Kong, State Key Laboratory for Brain and 
Cognitive Sciences
Background: Evidence shows that schizophrenia is associated with increased 
incidence of cardiovascular diseases (CVD), including stroke. The relation-
ship between schizophrenia and post-stroke mortality was understudied, 
and mixed findings were observed. Of note, none of these studies specifi-
cally explored the association of schizophrenia with short-term mortality 
after incident ischemic stroke. One of them specifically examined short-
term mortality following ischemic stroke in schizophrenia patients, but it 
did not address potential confounding by patients who had past history of 
stroke. The only study which included solely incident stroke patients indi-
cated that patients with psychotic disorders experienced higher short-term 
mortality ensuing incident stroke.
Methods: We conducted a retrospective cohort study to investigate short-
term mortality of schizophrenia patients after incident ischemic stroke. All 
individuals admitted for incident ischemic stroke between 2006 and 2016 in 
Hong Kong were identified using a territory-wide electronic health record 
database. 817 patients with an ICD-10 diagnosis of schizophrenia (F20) 
or schizoaffective disorder (F25) (termed schizophrenia henceforth) prior 
to index admission constituted the study group. The comparison group 
comprised 8170 patients (10:1 matched to schizophrenia patients on age, 
sex, treatment sites and calendar-period for index admission) without any 
non-affective psychoses, mania or bipolar disorder (F20, F22-25, F28-31).
Results: Multivariate logistic regression revealed that schizophrenia 
patients had higher 1-year (OR [95% CI] = 1.51 [1.22 – 1.85]) and margin-
ally higher 30-day (OR [95% CI] = 1.34 [1.00 – 1.79]) mortality following in-
cident ischemic stroke, after adjusting for medical comorbidities, including 
hypertension, diabetes, hyperlipidemia, alcohol and substance use disorders 
and other comorbidities quantified by Charlson-Deyo comorbidity index. 
Additional age- (<65 years and ≥65 years) and gender-stratified analyses 
revealed similar results. Elevated 1-year mortality was exhibited by all 
schizophrenia subgroups, being more pronounced in younger patients (OR 
[95% CI] = 2.02 [1.38 – 2.96]). Increase in 30-day mortality was only seen in 
younger (OR [95% CI] = 1.75 [1.04 – 2.95]) and male (OR [95% CI] = 1.63 
[1.06 – 2.50]) schizophrenia patients.
Discussion: Our results of heightened short-term post-stroke mortality in 
schizophrenia were in line with the only previous study which compared 
short-term mortality ensuing incident stroke in patients with and without 
psychotic disorders. This intuitive result may be explained by some studies 
which demonstrated that schizophrenic stroke patients were less likely to re-
ceive reperfusion treatments and prophylactic medications. The absence of 
data on lifestyle factors, antipsychotic treatment and post-stroke manage-
ment is a major limitation in our study. In conclusion, our results indicated 
that schizophrenia is associated with increased short-term mortality after 
incident ischemic stroke. Further research is warranted to clarify the con-
tribution of possible risk factors to post-stroke mortality in schizophrenia 
patients.
T79. BALANCING EFFECTS WITH SIDE-
EFFECTS: EXAMINING COMPARATIVE 
METABOLIC CONSEQUENCES OF 18 
ANTIPSYCHOTICS IN TREATMENT OF 
SCHIZOPHRENIA USING NETWORK 
META-ANALYSIS
Toby Pillinger*1, Rob McCutcheon1, Orestis Efthimiou2,  
Andrea Cipriani3, Oliver Howes1
1Institute of Psychiatry, King’s College London; 2Institute of Social 
and Preventive Medicine, University of Bern; 3University of Oxford
Background: Antipsychotic treatment is associated with metabolic distur-
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in treatment with different antipsychotics remains unclear. Furthermore, 
predictors of metabolic dysregulation are poorly understood, and as-
sociation between metabolic-change and change in psychopathology is 
uncertain.
Methods: We searched Medline, EMBASE and PsychINFO from incep-
tion until June 30, 2019. We included blinded randomised controlled trials 
(RCTs) comparing 18 antipsychotics and placebo in acute-treatment of 
schizophrenia. We performed frequentist random-effects network meta-
analyses (NMAs) to investigate treatment-induced changes in body 
weight, BMI, total/LDL/HDL-cholesterol, triglycerides, and glucose. We 
performed meta-regressions to examine relationships between metabolic 
change and age/gender/ethnicity/baseline-weight/baseline-metabolic pa-
rameter level. We examined the association between metabolic change and 
psychopathology change by estimating the correlation between symptom 
severity change and metabolic parameter change.
Results: Of 6532 citations, 100 RCTs met inclusion criteria, including 
25,952 patients. Median treatment-duration was 6-weeks. According to our 
NMAs, mean differences for weight-gain compared to placebo ranged from 
-0.23 (95% CI: -0.83, 0.36) for best (haloperidol) to +3.01kg (1.78, 4.24) 
for worst (clozapine); for BMI from -0.25 (-0.68, 0.17) for best (haloper-
idol) to +1.07kg/m2 (0.90, 1.25) for worst (olanzapine); for total-cholesterol 
from -0.09 (-0.24, 0.07) for best (cariprazine) to +0.56mmol/L (0.26, 0.86) 
for worst (clozapine); for LDL-cholesterol from -0.13 (-0.21, -0.05) for best 
(cariprazine) to +0.20mmol/L (0.14, 0.26) for worst (olanzapine); for HDL-
cholesterol from +0.05 (0.00, 0.10) for best (brexpiprazole) to -0.10mmol/L 
(-0.33, 0.14) for worst (amisulpride); for triglycerides from -0.01 (-0.10, 0.08) 
for best (brexpiprazole) to +0.98mmol/L (0.48, 1.49) for worst (clozapine); 
for glucose from -0.29 (-0.55, -0.03) for best (lurasidone) to 1.05mmol/L 
(0.41, 1.70) for worst (clozapine). Greater increases in glucose were 
predicted by higher baseline-weight (p=0.001) and male-gender (p=0.008). 
Non-Caucasian ethnicity was associated with greater increases in total-
cholesterol (p=0.04). Improvements in symptom severity were associated 
with increases in weight (rho=0.36, p=0.002), BMI (rho=0.84, p<0.0001), 
total-cholesterol (rho=0.31, p<0.05), and LDL-cholesterol (rho=0.42, 
p=0.01), and decreases in HDL-cholesterol (rho= -0.35, p=0.04).
Discussion: There are marked differences between antipsychotics in 
terms of metabolic side-effects, with olanzapine and clozapine exhibiting 
the worst profiles. By contrast, compared with placebo, lurasidone and 
cariprazine respectively reduce fasting glucose and LDL-cholesterol, 
while aripiprazole and brexpiprazole increase HDL-cholesterol. Baseline 
weight, male gender, and non-Caucasian ethnicity predict vulnerability to 
antipsychotic-induced metabolic change. Considering the increased prev-
alence of metabolic syndrome, cardiovascular disease, and cardiovascular 
mortality in schizophrenia, these data may be used to inform antipsychotic-
prescribing, especially in those at-risk groups we have identified. However, 
clinical decisions to preferentially use an antipsychotic with fewer meta-
bolic side effects should consider that clinical improvement appears to be 
associated with development of these side effects.
T80. CARDIOMETABOLIC RISK PREDICTION 
ALGORITHMS AND THEIR APPLICABILITY 
FOR YOUNG PEOPLE WITH PSYCHOSIS: 
A SYSTEMATIC REVIEW AND ILLUSTRATIVE 
EXAMPLE USING ORIGINAL DATA FROM 
A POPULATION-BASED BIRTH COHORT
Soomin Jang*1, Owen Crawford1, Benjamin Perry1,  
Peter B. Jones1, Golam Khandaker1
1University of Cambridge
Background: Cardiometabolic risk prediction algorithms are used in clinical 
practice. Young people with psychosis are a high-risk group for developing 
cardiometabolic disorders, but it is unclear whether existing algorithms are 
suitable for this group.
Methods: We conducted a systematic review employing PRISMA 
criteria to identify studies reporting the development and/or validation 
of cardiometabolic risk prediction algorithms for general or psychiatric 
populations. A narrative synthesis was conducted to compare algorithms 
and consider their suitability for young people with psychosis. In addition, 
we used data from 3,470 young adults aged 18  years from the ALSPAC 
birth cohort to illustrate the impact of age on model performance of 
QDiabetes, an established algorithm.
Results: Having screened 6,609 studies, we included 57 risk algorithms 
designed for type 2 diabetes, cardiovascular disease or stroke, all of which 
were developed/validated in relatively older participants. Three algorithms 
featured psychiatric predictors and could be used for young people with 
psychosis. However, in all of three, age was weighted to a much greater 
extent than other risk factors. Furthermore, using ALSPAC data, we re-
port that QDiabetes significantly under-predicted cardiometabolic risk in 
young people. Increasing the sample age to 50, leaving all other predictors 
unchanged, improved algorithm calibration markedly.
Discussion: Existing cardiometabolic risk prediction algorithms are heavily 
weighted on age and so under-predict risk in young people. A  new or 
recalibrated algorithm is required for young people with psychosis that ap-
propriately balances the weighting of relevant risk factors.
T81. MULTIPLE DRUG USE IN SCHIZOPHRENIA 
- THE ROLE OF EARLY ENVIRONMENTAL 
RISK ACCUMULATION AND GENETIC 
PREDISPOSITION
Agnes Steixner-Kumar*1, Jan Seidel1,  
Vinicius Daguano Gastaldi1, Martin Begemann1,  
Hannelore Ehrenreich1
1Max Planck Institute of Experimental Medicine, Göttingen
Background: Drug (ab)use and substance use disorders are frequently 
observed in patients with psychiatric illness, but the underlying causes re-
main widely unknown. A number of environmental risk factors have been 
proposed to affect the use of one or multiple drugs in the general popu-
lation and adolescents. Whereas most previous studies focused on the in-
fluence of single risk factors on the use of one or a few selected drugs, 
the effect of accumulated environmental risk in early life on multiple drug 
use remains to be studied. Similarly, evidence on genetic susceptibility to 
the (ab)use of a single drug, e.g. nicotine, alcohol, cocaine, is abundant, 
while the role of genetic predisposition for multiple drug use - in partic-
ular during early life - is yet to be explored. Thus, the current work aims 
to study the role of environmental as well as genetic risk factors for mul-
tiple drug abuse (‘polytoxicomania’) in a large sample of schizophrenic/
schizoaffective patients.
Methods: Information from ~2000 schizophrenia/schizoaffective patients 
on (preadult) multiple drug use (> 2 drugs) and environmental risk factors 
was extracted from the Göttingen Research Association for Schizophrenia 
(GRAS) data collection – currently the largest data base of deeply 
phenotyped patients with schizophrenia/schizoaffective disorder or other 
neuropsychiatric diseases. In addition, genetic data from these patients 
and 2111 healthy blood donors were used in a novel genetic approach 
that employs multiple genome-wide association studies (GWAS) to iden-
tify genetic associations with preadult multiple drug use. Genotyping 
was performed on a semi-custom Axiom MyDesign Genotyping Array 
(Affymetrix, Santa Clara, CA, USA), based on a CEU (Caucasian residents 
of European ancestry from UT, USA) marker backbone.
Results: The accumulation of  environmental risk factors, i.e. sexual 
abuse, physical abuse, migration, urbanicity, together with alcohol and 
cannabis consumption as secondary risk factors, in early life (< 18 years) 
were strongly associated with lifetime multiple drug use (p  =  3.48 x 
10^-44, extreme group comparison odds ratio (OR) = 31.8). When the 
sample was split into preadult and adult multiple drug users, there was 
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